William Marsh Rice University

Massachusetts Institute of Technology

Other

Children's Medical Center Corporation

The University of Texas System

University System of Maryland

Case Western Reserve University

Envisiontec Gmbh

Ambrose, Catherine G.

Clyburn, Terry A.

Mikos, Antonios G.

Siblani, Al

Wang, Martha O.

Fisher, John P.

Mott, Eric J.

Antonios Georgios Mikos

Michael J Yaszemski

Robert Samuel Langer

Joseph P Vacanti

H David Dean

Martha O Wang

Georgios Sarakinos

Linda G Griffith

John Patrick Fisher

Laura J Suggs

Al Siblani

Richard G Payne

Shulin He

Eric J Mott

John Fisher

Susan J Peter

F Kurtis Kasper

Seongbong Jo

John P Fisher

Tyler Joseph Touchet

Linda G Cima

Terry A Clyburn

Ali Siblani

Michael Hacker

Catherine G Ambrose

Paul S Engel

Kyobum Kim

Dimitrios P Kontoyiannis

Mark E Wong

Simon W Young

James D Kretlow

Patrick Spicer

Meng Shi

Martha Wang

Adam K Ekenseair

Alexander Mitchell Tatara

Tiffany N Vo

Kristel W M Boere

Emma Watson

Jonathan E Wallace

Kazuhiro Tanahashi

Michael Jr Yaszemski

David H Dean

A light polymerizable composition for use in the additive manufacturing of medical devices may include a first photo-initiator and a second photo-initiator. The first photo-initiator activates to initiate curing of the composition when exposed to light of a first wavelength in an additive manufacturing device and the second photo-initiator limits the transmission of the light of the first wavelength that activates the first photo-initiator in the additive manufacturing device. The second photo-initiator is activated to further cure the composition when exposed to a light of a second wavelength different from the first wavelength by activating the second photo-initiator to produce free radicals at a higher rate when exposed to the light of the second wavelength than when exposed to the light of the first wavelength.

Continuous digital light processing additive manufacturing of implants

A process for additive manufacturing of a resorbable implant to be implanted into a patient includes providing a biocompatible resin including a liquid light-polymerizable material that is resorbable after polymerization and an initiator. The process further includes actuating an additive manufacturing apparatus to expose an amount of the biocompatible resin to light to at least partially cure the exposed amount of biocompatible resin to form a layer of the resorbable implant and actuating the additive manufacturing apparatus to expose at least some additional amount of biocompatible resin to light to at least partially cure the exposed additional amount of biocompatible resin to form an additional layer of the resorbable implant and to at least partially overcure previously cured layers to cause at least some interlayer binding between the previously cured layers and the additional layer.

The disclosure relates to a class of diol-based, unsaturated aliphatic polyesters that biodegrade into monomers capable of mitigating infection. These poly(diol fumarates) (PDFs) and poly(diol fumarate-co-succinates) (PDFSs), can be crosslinked to form networks of scaffolds with antimicrobial degradation products. Both the diol carbon length and the degree of available double bonds are tunable, resulting in a highly controllable class of antimicrobial polymers useful for cell scaffolds and drug delivery systems and devices.

Poly(diol fumarates) and poly(diol fumarate-co-succinates)

A light-polymerizable composition for additive manufacturing of resorbable scaffolds and implants comprising a biocompatible resin. The biocompatible resin includes a combination of photo-initiators or a dye-initiator package tailored to manufacture implants with the desired physical and chemical properties. A dye or other constituent controls between layer (z) resolution of the manufactured part built in an additive manufacturing device. A light absorber or other constituent controls within layer (x-y) resolution of the manufactured part.

Absorbant and reflecting biocompatible dyes for highly accurate medical implants

Systems, methods and compositions useful for treatment of traumatic bone injuries are provided. In one embodiment, a bone reconstruction system comprising a space maintaining composition comprising porous polymethylmethacrylate; and an osseous generating construct comprising a polymethylmethacrylate chamber that comprises one or more osseous generating materials is provided. Associated compositions and methods are also provided.

Combined space maintenance and bone regeneration system for the reconstruction of large osseous defects

The present disclosure generally relates to injectable compositions. More particularly, the present disclosure relates to injectable, thermogelling hydrogels and associated methods. In one embodiment, the present disclosure provides for a composition comprising a poly(N-isopropylacrylamide)-based macromer and a polyamidoamine-based macromer.

Injectable hydrogels

Macromonomers capable of both physical crosslinking and chemical crosslinking. The combination of chemical crosslinking and physical crosslinking provides the ability to generate rapidly gelling hydrogels for many different applications. Moreover, the macromonomers may incorporate functional groups that allow for two different gelation mechanisms&#x2014;thermal gelation and ionic gelation&#x2014;further improving mechanical stability of hydrogels formed from the disclosed macromonomers.

Macromonomers and hydrogels

Polymeric materials are used to make a pliable, non-toxic, injectable porous template for vascular ingrowth. The pore size, usually between approximately 100 and 300 microns, allows vascular and connective tissue ingrowth throughout approximately 10 to 90% of the matrix following implantation, and the injection of cells uniformly throughout the implanted matrix without damage to the cells or patient. The introduced cells attach to the connective tissue within the matrix and are fed by the blood vessels. The preferred material for forming the matrix or support structure is a biocompatible synthetic polymer which degrades in a controlled manner by hydrolysis into harmless metabolites, for example, polyglycolic acid, polylactic acid, polyorthoester, polyanhydride, or copolymers thereof. The rate of tissue ingrowth increases as the porosity and/or the pore size of the implanted devices increases. The time required for the tissue to fill the device depends on the polymer crystallinity and is less for amorphous polymers versus semicrystalline polymers. The vascularity of the advancing tissue is consistent with time and independent of the biomaterial composition and morphology.

Method of forming a tissue structure by introducing cells into an implanted matrix

A cross-linkable monomer comprises a fumaric acid functional group having a first end and a second end, a first spacer group affixed to said first end and comprising at least repeating unit, a first terminal group affixed to said first spacer group, a second spacer group affixed to said second end and comprising at least one ethylene glycol repeating unit, and a second terminal group affixed to said second spacer group. A hydrogel formed by cross-linking the present monomer and a method for making the monomer. A method for forming a hydrogel, comprises the steps of a) synthesizing a copolymer of poly(propylene fumarate) (PPF) and poly(ethylene glycol (PEG) so as to produce P(PF-co-EG), b) synthesizing a PEG-tethered fumarate (PEGF), c) coupling agmatine sulfate to the PEGF to produce PEGF modified with agmatine (Agm-PEGF), and d) cross-linking the P(PF-co-EG) from step a) with Agm-PEGF from step c).

Synthesis and characterization of biodegradable cationic poly(propylene fumarate-co-ethylene glycol) copolymer hydrogels modified with agmatine for enhanced cell adhesion

Porous biodegradable polymeric materials for cell transplantation

A new oligomer based on alternating fumaric acid and poly(ethylene glycol) (PEG) units is provided. The oligo(PEG fumarate) (OPF) may be functionalized by modification with a biocompatible organic group. Further, the OPF may be cross-linked using radical polymerization in the presence of either a chemical or photo initiator. A cross-linked OPF gel has a swelling behavior that is tunable dependent on the molecular weight of PEG. A cross-linkable PEG macromer, as exemplified by oligo(PEG fumarate), has unsaturated double bonds, for example in the fumaryl groups, along its macromolecular chain that allows for the preparation of hydrogels with tailored structure and properties.

Biocompatible macromers

A network consisting essentially of poly(propylene fumarate) cross linked with diacrylate and a method for making same.

Biodegradable poly (propylene fumarate) networks cross linked with poly (propylene fumarate) -diacrylate macromers

A polymer network formed by crosslinking poly(propylene fumarate) with a fumarate derivative. The fumarate derivative is one in which the PPF is soluble, is preferably an alkyl fumarate, and is more preferably selected from the group consisting of diethyl fumarate, dimethyl fumarate, methyl ethyl fumarate, diisopropyl fumarate, and dibutyl fumarate. The network can be formed by photo-crosslinking and can be porous. In some embodiments, the poly(propylene fumarate) and the fumarate derivative are each present in an amount effective to produce a polymeric network useful for in vivo applications. The network can be formed from an injectable, in situ crosslinkable composite formulation, or can be prefabricated from a crosslinkable composite formulation such as stereolithography, rapid prototyping, injection molding, and extrusion molding.

Photocrosslinking of diethyl fumarate/poly(propylene fumarate) biomaterials

Polymeric materials are used,to make a pliable, non-toxic, injectable porous template for vascular ingrowth. The pore size, usually between approximately 100 and 300 microns, allows vascular and connective tissue ingrowth throughout approximately 10 to 90% of the matrix following implantation, and the injection of cells uniformly throughout the implanted matrix without damage to the cells or patient. The introduced cells attach to the connective tissue within the matrix and are fed by the blood vessels. The preferred material for forming the matrix or support structure is a biocompatible synthetic polymer which degrades in a controlled manner by hydrolysis into harmless metabolites, for example, polyglycolic acid, polylactic acid, polyorthoester, polyanhydride, or copolymers thereof. The rate of tissue ingrowth increases as the porosity and/or the pore size of the implanted devices increases. The time required for the tissue to fill the device depends on the polymer crystallinity and is less for amorphous polymers versus semicrystalline polymers. The vascularity of the advancing tissue is consistent with time and independent of the biomaterial composition and morphology.

Growing community of inventors

Houston, TX, United States of America

Antonios Georgios Mikos